Lantheus Downgraded to Neutral Amid Pricing Pressures and Acquisition UncertaintyLantheus Holdings (LNTH): More muted outlook from lingering pricing pressure and slower and PT to $77 8 October 2025 | 4:01AM EDT We see modest risk to intermediate-term consensus sales estimates; stock recovery tied to improving visibility on organic growth. Year-to-date, LNTH shares have significantly underperformed due to lingering pricing pressure on Pylarify, slower-than-anticipated uptake of approved Alzheimer's disease therapeutics, and a series of bolt-on acquisitions that have made the drivers of the company's future growth less predictable. While we see a mostly balanced risk/reward at current levels, a more sustained recovery in the stock is contingent upon improved visibility on organic growth, in our view. We downgrade LNTH to a new 12- month price target of $77 (from $110 prior). See within for details.